| Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141) |
|---|
| 05/04/2011 | CN101284820B Amino peptidase inhibiting substance and synthetic method |
| 05/04/2011 | CN101278991B Method for testing effective ingredients of Gegen Qinlian medicine |
| 05/04/2011 | CN101215544B Inflammation-inhibiting compounds |
| 05/04/2011 | CN101167833B Method for preparing raspberry superfine powder by gas phase, solid phase method superfine crushing technology |
| 05/04/2011 | CN101088555B Medicine preparation for inhibiting tumor angiogenesis and cancer cell and enhancing immunity |
| 05/04/2011 | CN101014580B Morpholine compound |
| 05/03/2011 | USRE42324 Compound for treatment of allergy and asthma |
| 05/03/2011 | US7935715 Compounds which modulate the CB2 receptor |
| 05/03/2011 | US7935692 Polyamine compounds are used to mobilize and harvest CD34+ cells via apheresis with and without combinations with other mobilizing factors; bind to chemokine receptors; regeneration of heart tissue |
| 05/03/2011 | US7935675 Immunostimulatory nucleic acid molecules |
| 05/03/2011 | US7935343 Immunoglobulin specific to interleukin-13 (IL-13) for use in prevention and treatment of asthma, fibrosis, skin and cell proliferative disorders |
| 05/03/2011 | CA2489824C Processes for preparing substituted pyrimidines and pyrimidine derivatives as inhibitors of protein kinases |
| 05/03/2011 | CA2473026C 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones |
| 05/03/2011 | CA2443632C Timed pulse release composition |
| 05/03/2011 | CA2440438C Heterocyclic compounds |
| 05/03/2011 | CA2438480C Glucocorticoid receptor modulators |
| 05/03/2011 | CA2347066C Isolated nucleic acid molecules which encode t cell inducible factors (tifs), the proteins encoded, and uses thereof |
| 05/03/2011 | CA2342966C Gene alteration in the gene for the gbeta3 subunit of the human g protein |
| 05/03/2011 | CA2293805C Use of mhc class ii ligands as adjuvant for vaccination and of lag-3 in cancer treatment |
| 04/28/2011 | WO2011050262A2 Dual variable domain immunoglobulins and uses thereof |
| 04/28/2011 | WO2011050054A2 Coumarin compounds as receptor modulators with therapeutic utility |
| 04/28/2011 | WO2011049677A1 Compounds and compositions as tlr activity modulators |
| 04/28/2011 | WO2011049291A2 Mesenchymal stem cell incorporating a nucleotide sequence coding tgfβ, and uses thereof |
| 04/28/2011 | WO2011049155A1 Process for production of quinuclidine compounds |
| 04/28/2011 | WO2011049053A1 Intestinal mucosa-inherent myeloid cells inhibiting t cell activation and utilization of same |
| 04/28/2011 | WO2011048936A1 Aminothiazole derivative |
| 04/28/2011 | WO2011048766A1 Carbonic anhydrase i serving as novel antigen to be used for treatment of autoimmune diseases |
| 04/28/2011 | WO2011048409A1 Cyclic amine derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
| 04/28/2011 | WO2011048082A1 Heterocyclyl pyrazolopyrimidine analogues as jak inhibitors |
| 04/28/2011 | WO2011047770A2 Pyrazolopyrimidine derivatives |
| 04/28/2011 | WO2011047631A1 Proteins or polypeptides with cd137l function and genes encoding the same and uses thereof |
| 04/28/2011 | WO2011005523A3 Galectin-immunoglobulin chimeric molecules |
| 04/28/2011 | WO2008017586A3 Special carbonyl-bis imino compounds for using as p2y11 receptor agonists in the treatment of immune diseases |
| 04/28/2011 | US20110098467 Pyrrolo-triazine aniline compounds useful as kinase inhibitors |
| 04/28/2011 | US20110098460 SiRNA Useful to Suppress expression of eIF-5A1 |
| 04/28/2011 | US20110098352 N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors |
| 04/28/2011 | US20110098308 Azaindazole compounds and methods of use |
| 04/28/2011 | US20110098302 Cyclic diaryl ether compounds as antagonists of prostaglandin d2 receptors |
| 04/28/2011 | US20110098288 Sulfonamides as zap-70 inhibitors |
| 04/28/2011 | US20110098280 2,4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
| 04/28/2011 | US20110098226 Small molecular weight TNF receptor multimeric molecule |
| 04/28/2011 | US20110097426 Methods for Safe and Effective Treatment Using Oxazaphosphorine Drugs |
| 04/28/2011 | US20110097417 Melan-a-carrier conjugates |
| 04/28/2011 | US20110097408 Chitosan-based matrices and uses thereof |
| 04/28/2011 | US20110097364 Macrocyclic lactone compounds and methods for their use |
| 04/28/2011 | US20110097362 Transmucosal Administration of Aggregated Antigens |
| 04/28/2011 | US20110097361 Method of inducing tolerance to an allergen |
| 04/28/2011 | US20110097360 Streptococcus pneumoniae pilus antigens |
| 04/28/2011 | US20110097359 Production of diphtheria toxin |
| 04/28/2011 | US20110097358 RESPIRATORY SYNCYTIAL VIRUS (RSV) VIRUS-LIKE PARTICLES (VLPs) |
| 04/28/2011 | US20110097357 Bioconjugates made from recombinant n-glycosylated proteins from procaryotic cells |
| 04/28/2011 | US20110097355 Virus-like particles as vaccines for paramyxovirus |
| 04/28/2011 | US20110097354 System for the expression of peptides on the bacterial surface |
| 04/28/2011 | US20110097353 Poultry viral materials and methods related thereto |
| 04/28/2011 | US20110097351 Compounds for treating beta-amyloidoses |
| 04/28/2011 | US20110097350 Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
| 04/28/2011 | US20110097348 Protein Formulation |
| 04/28/2011 | US20110097344 Compositions, Methods for Treatment, and Diagnoses of Autoimmunity-Related Disorders and Methods for Making Such Compositions |
| 04/28/2011 | US20110097339 Compositions monovalent for CD28 binding and methods of use |
| 04/28/2011 | US20110097337 Composition for eliciting a specific ctl response, comprising a lympho-ablative compound and a molecule that contains antigenic sequences and targets professional antigen presenting cells |
| 04/28/2011 | US20110097334 Novel Marker Genes for Regulatory T Cells from Human Blood |
| 04/28/2011 | US20110097332 Composition and Method of Use for HCV Immunization |
| 04/28/2011 | US20110097331 Antibodies that bind both il-17a and il-17f and methods of using the same |
| 04/28/2011 | US20110097330 Novel Gene Disruptions, Compostitions and Methods Relating Thereto |
| 04/28/2011 | US20110097327 Product and method for treatment of conditions associated with receptor-desensitization |
| 04/28/2011 | US20110097325 Modulation of T cell Differentiation for the treatment of T helper cell mediated diseases |
| 04/28/2011 | US20110097322 Partially loaded antibodies and methods of their conjugation |
| 04/28/2011 | US20110097314 Method for producing a composition for promoting survival of transplanted hematopoietic stem cell |
| 04/28/2011 | US20110097305 Gem-Disubstituted and Spirocyclic Amino Pyridines/Pyrimidines as Cell Cycle Inhibitors |
| 04/28/2011 | US20110097302 Il-1ra-polymer conjugates |
| 04/28/2011 | US20110097270 Monoclonal Antibodies That Bind or Neutralize Hepatitis B Virus |
| 04/28/2011 | DE102009043260A1 Pyridinyl-imidazolonderivate Pyridinyl-imidazolone derivatives |
| 04/28/2011 | CA2778611A1 Coumarin compounds as receptor modulators with therapeutic utility |
| 04/28/2011 | CA2777881A1 Pyrazolopyrimidine derivatives |
| 04/28/2011 | CA2775009A1 Heterocyclyl pyrazolopyrimidine analogues as jak inhibitors |
| 04/28/2011 | CA2772657A1 Compounds and compositions as tlr activity modulators |
| 04/27/2011 | EP2314695A2 Ligand for receptor activator of NF-kappa B, ligand is member of TNF superfamily |
| 04/27/2011 | EP2314694A2 BAFF receptor (BCMA), an immunoregulatory agent |
| 04/27/2011 | EP2314693A2 Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides |
| 04/27/2011 | EP2314676A1 Compositions and methods for the treatment of immune related diseases |
| 04/27/2011 | EP2314627A2 Method for the treatment of multiple sclerosis |
| 04/27/2011 | EP2314624A2 Human antibody molecules for IL-13 |
| 04/27/2011 | EP2314623A1 IL-1beta binding antibodies and fragments thereof |
| 04/27/2011 | EP2314601A1 Anti-inflammatory compounds and uses thereof |
| 04/27/2011 | EP2314585A1 Condensed benzamide compounds as inhibitors of vanilloid receptor subtype 1 (VR1) activity |
| 04/27/2011 | EP2314322A1 Compositions containing genetically modified lung cancer cells expressing a TGF-beta inhibitor |
| 04/27/2011 | EP2314315A1 A blocking monoclonal antibody to the human alpha1 I-domain of VLA-1, and its use for the treatment of inflammatory disorders |
| 04/27/2011 | EP2314312A2 Peptides and therapeutic application therefof |
| 04/27/2011 | EP2314311A2 Peptides and therapeutic application thereof |
| 04/27/2011 | EP2314293A1 Implantable device containing resorbable matrix material and rapamycin for preventing or treating vasuloproliferative diseases |
| 04/27/2011 | EP2313419A1 Novel compounds and methods for their production |
| 04/27/2011 | EP2313384A1 Phenyl-alkyl piperazines having a modulating activity of tnf |
| 04/27/2011 | EP2313372A1 Aminopyridine kinase inhibitors |
| 04/27/2011 | EP2313369A2 2-methylene-(20e)-20(22)-dehydro-19-nor-vitamin d analogs |
| 04/27/2011 | EP2313368A2 2-methylene-(17z)-17(20)-dehydro-19,21-dinor-vitamin d analogs |
| 04/27/2011 | EP2313367A2 2-methylene-19,26-dinor-(20r,22e,25r)-vitamin d analogs |
| 04/27/2011 | EP2313110A1 Effectors of par-2 activation and their use in the modulation of inflammation |
| 04/27/2011 | EP1670444B1 Use of indoleacetic acid derivatives which increase the serum igf-1 level for the preparation of a therapeutical composition for treatment of various diseases |
| 04/27/2011 | EP1477175B1 Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient |
| 04/27/2011 | EP1272633B1 Compositions and methods for dendritic cell-based immunotherapy |